A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 344 participants.
Also called NCT07481981
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 344 participants
- Sponsor
- Registry
-
NCT07481981 -
2026-525265-48-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Israel, Japan, New Zealand, South Korea, Taiwan
- Registry status
- Recruiting
Technical summary
Registry record NCT07481981. Randomized; double masking; primary purpose treatment. Start 2026-07-21 (actual); primary completion 2028-12-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
- Acronym
- PALM-PAH
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Treprostinil Palmitil Inhalation Powder
- Intervention (Drug)
- Placebo
- Lead sponsor
- Insmed Incorporated
Record details
- Record id
cardio:ct-nct07481981- Content hash
48474aba12714474ec9f738a8b2796fbc4f46a4baf3ca95dd5f4a57ef20cdb97